Werewolf Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recognized collaboration revenue of $21 million, a notable increase from zero revenue in the same period last year. This revenue stems from an asset purchase agreement with Jazz Pharmaceuticals, which involved the sale of the 898 Program, previously under a collaboration agreement. The company’s operating expenses for the quarter totaled $13.8 million, down from $17.5 million in the prior year, primarily due to reduced research and development costs following workforce reductions.
The company’s net income for the quarter was $3.7 million, a substantial improvement compared to a net loss of $18 million in the same quarter of 2025. For the first half of 2026, Werewolf reported a net loss of $9.9 million, significantly less than the $36.1 million loss reported in the first half of 2025. The reduction in losses is attributed to the aforementioned decrease in operating expenses and the recognition of revenue from the asset sale.
In terms of strategic developments, Werewolf initiated a restructuring plan in February 2026, which included a workforce reduction of approximately 64% to align resources with its strategic objectives. This was followed by an additional reduction of 36% in May 2026. The restructuring is expected to incur costs of approximately $6.5 million, which have already begun to impact the company’s financials. The company is currently exploring various strategic alternatives, including potential partnerships or sales of assets, to enhance stockholder value.
Operationally, Werewolf had cash and cash equivalents of $22 million as of June 30, 2026, a decrease from $57 million at the end of 2025. The company has raised concerns about its ability to continue as a going concern for at least the next twelve months, given its reliance on additional financing to support ongoing operations and product development. The company’s total liabilities decreased significantly to $7.9 million from $44.6 million at the end of 2025, primarily due to the repayment of a term loan agreement with K2 HealthVentures.
Looking ahead, Werewolf anticipates continued operating losses and negative cash flows as it navigates its strategic review process. The company is focused on completing clinical trials for its lead product candidates, WTX-124 and WTX-330, which are expected to conclude in late 2026. However, the company acknowledges that additional funding will be necessary to support these efforts and that the outcome of its strategic review will significantly influence its future development plans and financial requirements.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics is a biopharmaceutical company developing innovative immunotherapies for cancer and immune-mediated diseases. Using its proprietary PREDATOR platform, it engineers conditionally activated cytokine molecules (INDUKINE) that target the tumor microenvironment, aiming to enhance efficacy while minimizing toxicity. Its pipeline includes cytokine-based therapeutics like IL-2, IL-12, IL-21, IL-18, and IL-10, designed for systemic delivery and tumor-specific activation. The company focuses on immuno-oncology, autoimmune, and inflammatory disease treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov